I see value in this stock. Axiron sales in FY16 USD149.3m vs...

  1. 907 Posts.
    lightbulb Created with Sketch. 160
    I see value in this stock.

    Axiron sales in FY16 USD149.3m vs FY17 USD143m which is not materially different. If the patent appeal is successful, I expect sales to maintain at this level and dividends to return. If unsuccessful, we should make up some of the lost sales with our own generic product.
    Cash in the Bank was 32m as at 31 Dec 2016.

    I like the fact Acrux has a commercialized product generating good income to help fund the pipeline of work.
    One thing I don't like about this company (which has been discussed many times) is the poor communication and updates regarding the pipeline!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.9¢
Change
0.000(0.00%)
Mkt cap ! $7.747M
Open High Low Value Volume
1.9¢ 1.9¢ 1.9¢ $812 42.73K

Buyers (Bids)

No. Vol. Price($)
6 631825 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 522500 4
View Market Depth
Last trade - 13.06pm 20/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.